1. Home
  2. NMAI vs VALN Comparison

NMAI vs VALN Comparison

Compare NMAI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NMAI

Nuveen Multi-Asset Income Fund of Beneficial Interest

HOLD

Current Price

$13.87

Market Cap

452.6M

Sector

Finance

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$5.21

Market Cap

536.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMAI
VALN
Founded
2021
2012
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
452.6M
536.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NMAI
VALN
Price
$13.87
$5.21
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.50
AVG Volume (30 Days)
141.2K
31.3K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
13.14%
N/A
EPS Growth
N/A
N/A
EPS
0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$93.87
P/E Ratio
$21.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.99
$5.06
52 Week High
$14.38
$12.25

Technical Indicators

Market Signals
Indicator
NMAI
VALN
Relative Strength Index (RSI) 50.42 39.82
Support Level $13.52 $5.11
Resistance Level $13.86 $6.60
Average True Range (ATR) 0.29 0.25
MACD -0.06 -0.04
Stochastic Oscillator 55.88 15.77

Price Performance

Historical Comparison
NMAI
VALN

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: